Regulatory T cell transfer ameliorates lymphedema and promotes lymphatic vessel function

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Secondary lymphedema is a frequent complication following cancer treatment, with poorly understood pathological mechanisms and no existing cure.
• Current understanding of lymphedema pathogenesis is limited, necessitating further investigation into underlying molecular and cellular processes.

Purpose of the Study:

• To elucidate the pathological mechanisms of secondary lymphedema using a top-down genomic approach.
• To investigate the specific role of regulatory T cells (Tregs) in lymphedema development and progression.
• To evaluate the therapeutic potential of Treg-based interventions for lymphedema.

Main Methods:

• RNA sequencing of lymphedematous mouse skin to identify key molecular pathways.
• Genetic manipulation of regulatory T cells (Tregs) in mouse models to assess their function (loss-of-function and gain-of-function studies).
• Adoptive transfer of Tregs as a potential therapeutic strategy in established lymphedema models.

Main Results:

• Genomic analysis revealed significant upregulation of T cell-related networks, with CD4+ cell depletion attenuating lymphedema.
• Increased infiltration of regulatory T cells (Tregs), marked by Foxp3 expression, was observed in both mouse and human lymphedema tissues.
• Treg depletion exacerbated lymphedema, while Treg expansion and adoptive transfer significantly ameliorated edema, inflammation, fibrosis, and improved lymphatic function.

Conclusions:

• Regulatory T cells (Tregs) are key players in the pathogenesis of secondary lymphedema.
• Treg-based therapies, including adoptive transfer, demonstrate significant potential for reversing lymphedema and represent a promising curative treatment strategy.